219 related articles for article (PubMed ID: 15349717)
1. The impact of thiopurine S-methyltransferase polymorphisms on azathioprine dose 1 year after renal transplantation.
Fabre MA; Jones DC; Bunce M; Morris PJ; Friend PJ; Welsh KI; Marshall SE
Transpl Int; 2004 Oct; 17(9):531-9. PubMed ID: 15349717
[TBL] [Abstract][Full Text] [Related]
2. TPMT genotype and its clinical implication in renal transplant recipients with azathioprine treatment.
Song DK; Zhao J; Zhang LR
J Clin Pharm Ther; 2006 Dec; 31(6):627-35. PubMed ID: 17176368
[TBL] [Abstract][Full Text] [Related]
3. The impact of thiopurine s-methyltransferase polymorphism on azathioprine-induced myelotoxicity in renal transplant recipients.
Kurzawski M; Dziewanowski K; Gawrońska-Szklarz B; Domański L; Droździk M
Ther Drug Monit; 2005 Aug; 27(4):435-41. PubMed ID: 16044099
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetics of thiopurine therapy in paediatric IBD patients.
De Ridder L; Van Dieren JM; Van Deventer HJ; Stokkers PC; Van der Woude JC; Van Vuuren AJ; Benninga MA; Escher JC; Hommes DW
Aliment Pharmacol Ther; 2006 Apr; 23(8):1137-41. PubMed ID: 16611274
[TBL] [Abstract][Full Text] [Related]
5. Thiopurine S-methyltransferase polymorphism in Iranian kidney transplant recipients.
Aghdaie MH; Azarpira N; Geramizadeh B; Sagheb M; Darai M; Rahsaz M; Malekhoseini SA
Exp Clin Transplant; 2011 Aug; 9(4):241-6. PubMed ID: 21819368
[TBL] [Abstract][Full Text] [Related]
6. Thiopurine methyltransferase gene polymorphisms in Chinese patients with inflammatory bowel disease.
Cao Q; Zhu Q; Shang Y; Gao M; Si J
Digestion; 2009; 79(1):58-63. PubMed ID: 19252404
[TBL] [Abstract][Full Text] [Related]
7. Importance of thiopurine S-Methyltransferase gene polymorphisms for prediction of azathioprine toxicity.
Kolorz M; Bartosova L; Hosek J; Dvorackova D; Chylkova A; Zboril V; Batovsky M; Bartos M
Neuro Endocrinol Lett; 2009; 30 Suppl 1():137-42. PubMed ID: 20027160
[TBL] [Abstract][Full Text] [Related]
8. Azathioprine-induced fatal myelosuppression in systemic lupus erythematosus patient carrying TPMT*3C polymorphism.
Boonsrirat U; Angsuthum S; Vannaprasaht S; Kongpunvijit J; Hirankarn N; Tassaneeyakul W; Avihingsanon Y
Lupus; 2008 Feb; 17(2):132-4. PubMed ID: 18250137
[TBL] [Abstract][Full Text] [Related]
9. Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine.
Dilger K; Schaeffeler E; Lukas M; Strauch U; Herfarth H; Müller R; Schwab M
Ther Drug Monit; 2007 Feb; 29(1):1-5. PubMed ID: 17304143
[TBL] [Abstract][Full Text] [Related]
10. Genetic determinants of the pre- and post-azathioprine therapy thiopurine methyltransferase activity phenotype.
Arenas M; Duley JA; Ansari A; Shobowale-Bakre EA; Fairbanks L; Soon SY; Sanderson J; Marinaki AM
Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1403-5. PubMed ID: 15571267
[TBL] [Abstract][Full Text] [Related]
11. The role of genetic variation in thiopurine methyltransferase activity and the efficacy and/or side effects of azathioprine therapy in dermatologic patients.
Snow JL; Gibson LE
Arch Dermatol; 1995 Feb; 131(2):193-7. PubMed ID: 7857117
[TBL] [Abstract][Full Text] [Related]
12. [Association between metabolic enzyme genotype of azathioprine and drug tolerance in patients with rheumatic diseases].
Zhan ZP; Liang LQ; Yang XY; Wang YX; Huang M; Li H
Zhonghua Yi Xue Za Zhi; 2007 Jul; 87(25):1734-7. PubMed ID: 17919375
[TBL] [Abstract][Full Text] [Related]
13. Relationships between thiopurine S-methyltransferase polymorphism and azathioprine-related adverse drug reactions in Chinese renal transplant recipients.
Xin HW; Xiong H; Wu XC; Li Q; Xiong L; Yu AR
Eur J Clin Pharmacol; 2009 Mar; 65(3):249-55. PubMed ID: 19048245
[TBL] [Abstract][Full Text] [Related]
14. Thiopurine dose in intermediate and normal metabolizers of thiopurine methyltransferase may differ three-fold.
Gardiner SJ; Gearry RB; Begg EJ; Zhang M; Barclay ML
Clin Gastroenterol Hepatol; 2008 Jun; 6(6):654-60; quiz 604. PubMed ID: 18467186
[TBL] [Abstract][Full Text] [Related]
15. An audit of thiopurine methyltransferase genotyping and phenotyping before intended azathioprine treatment for dermatological conditions.
Vestergaard T; Bygum A
Clin Exp Dermatol; 2010 Mar; 35(2):140-4. PubMed ID: 19663853
[TBL] [Abstract][Full Text] [Related]
16. Analysis of thiopurine S-methyltransferase polymorphism in the population of Serbia and Montenegro and mercaptopurine therapy tolerance in childhood acute lymphoblastic leukemia.
Dokmanovic L; Urosevic J; Janic D; Jovanovic N; Petrucev B; Tosic N; Pavlovic S
Ther Drug Monit; 2006 Dec; 28(6):800-6. PubMed ID: 17164697
[TBL] [Abstract][Full Text] [Related]
17. Choice of azathioprine or 6-mercaptopurine dose based on thiopurine methyltransferase (TPMT) activity to avoid myelosuppression. A prospective study.
Gisbert JP; Luna M; Maté J; González-Guijarro L; Cara C; Pajares JM
Hepatogastroenterology; 2006; 53(69):399-404. PubMed ID: 16795981
[TBL] [Abstract][Full Text] [Related]
18. Thiopurine S-methyltransferase genotype and the use of thiopurines in paediatric inflammatory bowel disease Greek patients.
Gazouli M; Pachoula I; Panayotou I; Mantzaris G; Syriopoulou VP; Goutas N; Vlachodimitropoulos D; Anagnou NP; Roma-Giannikou E
J Clin Pharm Ther; 2010 Feb; 35(1):93-7. PubMed ID: 20175817
[TBL] [Abstract][Full Text] [Related]
19. Severe azathioprine-induced myelotoxicity in a kidney transplant patient with thiopurine S-methyltransferase-deficient genotype (TPMT*3A/*3C).
Kurzawski M; Dziewanowski K; Ciechanowski K; Droździk M
Transpl Int; 2005 May; 18(5):623-5. PubMed ID: 15819814
[No Abstract] [Full Text] [Related]
20. Current use of pharmacogenetic testing: a national survey of thiopurine methyltransferase testing prior to azathioprine prescription.
Fargher EA; Tricker K; Newman W; Elliott R; Roberts SA; Shaffer JL; Bruce I; Payne K
J Clin Pharm Ther; 2007 Apr; 32(2):187-95. PubMed ID: 17381669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
